Back

Safety and efficacy of CR-Pregabalin found to be similar to IR-Pregabalin in fibromyalgia

Medical News 3 min 139

Font Size

Created On: 22/01/2020

Safety and efficacy of CR-Pregabalin found to be similar to IR-Pregabalin in fibromyalgia

What's new?

The safety and efficacy of controlled-release and immediate-release pregabalin are comparable for the treatment of fibromyalgia.

According to a recent study published in Journal Expert Review of Neurotherapeutics, PGB-CR (Pregabalin controlled-release) shows similar safety and efficacy as PGB-IR (Pregabalin immediate-release). Fibromyalgia (FM) is a condition that involves fatigue, cognitive impairment, musculoskeletal pain and sleep disturbances. Due to these problems, this disease dramatically affects the occupational, social and personal life. The pregabalin is an anticonvulsant and antidepressants; milnacipran and duloxetine are the FDA approved drugs for FM treatment.

This narrative review proposed to evaluate data associated with PGB-CR

Safety and efficacy to manage FM. The pharmaceutical industry derived new formulations of previously licensed drugs to improve treatment compliance and adherence. There is no specific study regarding PGB-CR and PGB-IR formulations comparison, but the safety and efficacy of both drugs seem to be comparable. With once daily dose the patients' compliance also increased. However, more research on large population is required to validate the findings further.